- Home
- KALV vs ESPR Comparison
KALV vs ESPR Comparison
Compare KALV & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- ESPR
- Stock Information
- Founded
- KALV N/A
- ESPR 2008
- Country
- KALV United States
- ESPR United States
- Employees
- KALV N/A
- ESPR N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- KALV Health Care
- ESPR Health Care
- Exchange
- KALV Nasdaq
- ESPR Nasdaq
- Market Cap
- KALV 362.2M
- ESPR 410.2M
- IPO Year
- KALV N/A
- ESPR 2013
- Fundamental
- Price
- KALV $10.03
- ESPR $1.82
- Analyst Decision
- KALV Strong Buy
- ESPR Buy
- Analyst Count
- KALV 8
- ESPR 6
- Target Price
- KALV $25.67
- ESPR $7.25
- AVG Volume (30 Days)
- KALV 321.8K
- ESPR 3.3M
- Earning Date
- KALV 03-10-2025
- ESPR 03-04-2025
- Dividend Yield
- KALV N/A
- ESPR N/A
- EPS Growth
- KALV N/A
- ESPR N/A
- EPS
- KALV N/A
- ESPR N/A
- Revenue
- KALV N/A
- ESPR $295,451,000.00
- Revenue This Year
- KALV N/A
- ESPR $186.86
- Revenue Next Year
- KALV N/A
- ESPR $9.41
- P/E Ratio
- KALV N/A
- ESPR N/A
- Revenue Growth
- KALV N/A
- ESPR 187.12
- 52 Week Low
- KALV $7.30
- ESPR $1.58
- 52 Week High
- KALV $15.50
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- KALV 59.09
- ESPR 38.40
- Support Level
- KALV $8.99
- ESPR $1.82
- Resistance Level
- KALV $11.00
- ESPR $1.91
- Average True Range (ATR)
- KALV 0.57
- ESPR 0.09
- MACD
- KALV 0.11
- ESPR 0.02
- Stochastic Oscillator
- KALV 57.08
- ESPR 47.83
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.